TREATMENT READING
Rectal Cancer
Choose a source section by treatment, subtype or setting. Patient and professional reading are labelled separately.
Selected text from the National Cancer Institute, with original links and dates. This Triangle reading page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.
33 studies cited in this topic · see design and results →
Explore 9 related disease and treatment settings → · Source-derived catalogue; clinical review pending.
Follow-Up After Treatment
Carcinoembryonic antigen (CEA)
Treatment Option Overview for Rectal Cancer
Immunotherapy
Primary Surgical Therapy
Chemoradiation Therapy
Preoperative chemoradiation therapy
Postoperative chemoradiation therapy
Chemotherapy regimens
Total neoadjuvant therapy
Treatment toxicity
Long-course versus short-course radiation therapy
Capecitabine and fluorouracil dosing
Treatment of Stage 0 Rectal Cancer
Treatment Options for Stage 0 Rectal Cancer
Polypectomy or surgery
Treatment of Stage I Rectal Cancer
Treatment Options for Stage I Rectal Cancer
Surgery with or without chemoradiation therapy
Treatment of Stages II and III Rectal Cancer
Treatment Options for Stages II and III Rectal Cancer
Preoperative chemoradiation therapy
Neoadjuvant chemotherapy with FOLFOX without preoperative chemoradiation therapy (for select patients with lower-risk disease)
Short-course preoperative radiation therapy followed by surgery and chemotherapy
Postoperative chemoradiation therapy
Surgery
Primary chemoradiation therapy followed by intensive surveillance for complete clinical responders
Immunotherapy
Chemotherapy regimens
Preoperative oxaliplatin with chemoradiation therapy
Postoperative oxaliplatin-containing regimens
Treatment of Stage IV and Recurrent Rectal Cancer
Treatment Options for Stage IV and Recurrent Rectal Cancer
Surgery with or without chemotherapy or radiation therapy
Systemic therapy
5-FU
Irinotecan and oxaliplatin
Capecitabine
Bevacizumab
FOLFOXIRI
Cetuximab
Ziv-aflibercept
Ramucirumab
Panitumumab
Anti-EGFR antibody versus anti-VEGF antibody with first-line chemotherapy
Regorafenib
Fruquintinib
Trifluridine-tipiracil
Encorafenib with cetuximab for patients with BRAF V600E variants
Sotorasib with panitumumab for patients with KRAS G12C variants
Second-line chemotherapy
Immunotherapy
First-line immunotherapy
Pembrolizumab monotherapy
Nivolumab and ipilimumab
Second-line immunotherapy
Pembrolizumab monotherapy
Nivolumab monotherapy
Nivolumab and ipilimumab
Palliative therapy
Treatment of Liver Metastasis
Surgery
Neoadjuvant chemotherapy for unresectable liver metastases
Local ablation for unresectable liver metastases
Adjuvant chemotherapy
Intra-arterial chemotherapy after liver resection
Preserved source evidence · Independent clinical review pending · Not medical advice
Triangle